Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Canadian Cardiovascular Society/Canadian Heart Failure Society joint position statement on the evaluation and management of patients with cardiac amyloidosis.Can J Cardiol. 2020; 36: 322-334
- 2017 Comprehensive update of the Canadian Cardiovascular Society guidelines for the management of heart failure.Can J Cardiol. 2017; 33: 1342-1433
- Optimizing access to heart failure care in canada during the COVID-19 pandemic.Can J Cardiol. 2020; 36: 1148-1151
- Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.N Engl J Med. 2018; 379: 1007-1016
- ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2—diagnostic criteria and appropriate utilization.J Nucl Cardiol. 2019; 27: 659-673
See page 677 for disclosure information.